Evidence map›Paper›PMID 39569197›Full record

ArticleFrontiers in immunology2024

Determination of immunogenicity of an inactivated ND-vaccine developed experimentally with Newcastle disease virus (Genotype VII.2) local isolates of Bangladesh.

Mohammad Aynul Haque, Md Enamul Haque, Mst Kohinoor Parvin, Md Mostofa Kamal, Tanbin Rubaiya Islam, Mohammad Sadekuzzaman, Md Ariful Islam, Mst Minara Khatun, Muhammad Tofazzal Hossain, Mohammad Asir Uddin and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mohammad Aynul HaqueDepartment of Microbiology and Hygiene, Bangladesh Agricultural University, Mymensingh, Bangladesh.
Md Enamul HaqueDepartment of Microbiology and Hygiene, Bangladesh Agricultural University, Mymensingh, Bangladesh.
Mst Kohinoor ParvinDepartment of Microbiology and Hygiene, Bangladesh Agricultural University, Mymensingh, Bangladesh.
Md Mostofa KamalDepartment of Microbiology and Hygiene, Bangladesh Agricultural University, Mymensingh, Bangladesh.
Tanbin Rubaiya IslamDepartment of Microbiology and Hygiene, Bangladesh Agricultural University, Mymensingh, Bangladesh.
Mohammad SadekuzzamanCentral Disease Investigation Laboratory, Department of Livestock Services, Dhaka, Bangladesh.
Md Ariful IslamDepartment of Microbiology and Hygiene, Bangladesh Agricultural University, Mymensingh, Bangladesh.
Mst Minara KhatunDepartment of Microbiology and Hygiene, Bangladesh Agricultural University, Mymensingh, Bangladesh.
Muhammad Tofazzal HossainDepartment of Microbiology and Hygiene, Bangladesh Agricultural University, Mymensingh, Bangladesh.
Mohammad Asir UddinDepartment of Microbiology and Hygiene, Bangladesh Agricultural University, Mymensingh, Bangladesh.
Sham Soun NaharLivestock Research Institute, Department of Livestock Services, Dhaka, Bangladesh.
A K M KhasruzzamanDepartment of Microbiology and Hygiene, Bangladesh Agricultural University, Mymensingh, Bangladesh.
Md Alimul IslamDepartment of Microbiology and Hygiene, Bangladesh Agricultural University, Mymensingh, Bangladesh.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Newcastle disease virus (NDV) genotype VII severely affects poultry, causing respiratory and neurological symptoms with a high rate of morbidity and mortality. The research aimed to develop an inactivated ND vaccine using local isolates (Genotype VII.2) and assess its immunogenicity compared to other commercial live ND vaccines. Methods: An inactivated vaccine using a candidate NDV (GenBank: OR924274.1) was developed according to WOAH guidelines following inactivation, sterility, purity, and safety tests. The birds were vaccinated through subcutaneous (SC) and intramuscular (IM) routes using three doses (0.25, 0.5, and 1.0 ml/bird). Immunogenicity and protective potentiality of the experimentally developed inactivated ND vaccine and live commercial ND vaccine (intra-ocularly/IO) were compared by challenge studies using three vaccination schedules: killed-followed-killed, live-followed-killed, and live-followed-live. Results: The birds vaccinated with 1.0 ml/bird SC showed higher antibody titers compared to those of IM-vaccinated groups. Birds vaccinated with the live-followed-killed commercial ND vaccines had slightly higher antibody titers compared to those vaccinated with killed-followed-killed and live-followed-live vaccines. Birds vaccinated with the killed-followed-killed ND vaccine showed a higher protection rate (100%) compared to live-followed-killed (83±5.77%) and live-followed-live (57±5.77%) vaccines. Birds vaccinated with killed-followed-killed group showed a slower decline rate of antibody titers than other groups. This regimen provided significantly better immunity, highlighting its potential in controlling ND outbreaks in Bangladesh's poultry. Conclusion: The study found that the inactivated ND vaccine, developed with the locally circulating isolate of genotype-VII.2 of NDV, might play an important role in effective control and management of ND in the commercial poultry population in Bangladesh.

Indexed as

Antibodies, ViralChickensGenotypeNewcastle DiseaseNewcastle disease virusPoultry DiseasesVaccines, InactivatedViral VaccinesAnimalsBangladeshImmunogenicity, VaccineVaccinationVaccines, AttenuatedAntibodies, ViralVaccines, AttenuatedVaccines, InactivatedViral Vaccinesantibody titersimmunogenicityinactivated ND vaccineNDV genotype VII.2protective potentiality

Identifiers

PMID39569197
PMCPMC11576377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.